Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer

British Journal of Cancer

Volumn 91, Issue 5, 2004, Pages 839-843

  Rao, S ^a   Cunningham, D ^a   Price, T ^b   Hill, M E ^a   Ross, P J ^a   Tebbutt, N ^a   Norman, A R ^a   Oates, J ^a   Shellito, P ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Advanced; Capecitabine; Chemotherapy; Colorectal cancer; Mitomycin C

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; GEFITINIB; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOMYCIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4644240651     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602039     Document Type: Article

References (23)

1. Aparicio T, Desrame J, Lecomte T, Mitry E, Belloc J, Etienney I, Montembault S, Vayre L, Locher C, Ezenfis J, Artru P, Mabro M, Dominguez S (2003) Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer 89: 1439-1444
2. Capecitabine Usage Tracking Study. The Research Partnership (2004)
3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047
5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22: 23-30
6. Grothey A, Jordan K, Kellner O (2003) Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 22(1022): 255
7. Meta-analysis Group In Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308
8. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281
9. Munoz A, Salut P, Escudero P (2003) Irinotecan (CPT-11) and capecitabine (C) as first line treatment of locally advanced or metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 22: 317
10. Parkin DM, Bray FI, Devesa SS (2001b) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8): S4-S66
11. Parkin DM, Bray F, Ferlay J, Pisani P (2001a) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94: 153-156
12. Piedbois P, Michiels S, for the Meta-Analysis Group In Cancer (2003) Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: an updated meta-analysis based on 2751 patients. Proc Am Soc Clin Oncol 22(1180): 294
13. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D (1999) Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17: 2412-2418
14. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R, Oates J (1997) A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 8: 995-1001
15. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S (2001) Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19: 3801-3807
16. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914
17. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H (1998) Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 4: 1013-1019
18. Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45: 291-297
19. Shields AF, Zalupski MM, Marshall JL, Meropol NJ (2004) Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 100(3): 531-537
20. Tabernero JM, Butts JA, Cassidy J (2002) Capecitabine oxaliplatin in combination (Xelox) as first line therapy for patients (pts) with metastatic colorectal cancer (MCRC): results of an international multicenter phase II trial. Proc Am Soc Clin Oncol 21(1): 133
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
22. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W (2000) Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47: 13-47
23. Twelves C (2002) Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer 38(Suppl 2): 15-20